Published in Business

Johnson & Johnson to acquire Ollin Biosciences in deal worth up to $3.3B

This is editorially independent content
6 min read

Johnson & Johnson has entered into a definitive agreement to purchase Ollin Biosciences as part of a deal worth up to $3.3 billion.

The company also announced a separate funding deal with Blackstone Life Sciences.

Let’s get a look at these players.

Starting with J&J: Operating out of New Jersey, this big-name drug maker most recently posted +5.1% in its vision business (under the MedTech branch) and +5.9% sales growth for the company as a whole for Q3 2026.

  • As of Monday (Nov. 16): The company ‘s market cap was an estimated $688 billion.

And in recent news: J&J has been busy rolling out updates to its ACUVUE OASYS contact lens and TECNIS PureSee intraocular lens (IOL) to the U.S. commercial market this past year.

See here for more coverage.

And Ollin Biosciences?

The clinical-stage biopharmaceutical company is relatively new to the ophthalmic space: After its initial establishment in 2023, it made a renewed debut in September 2025.

  • At the helm: an executive team led by co-founder and CEO Jason Ehrlich, MD, PhD—best known as the former chief medical and development officer at Kodiak Sciences.

So what’s the company’s scientific focus?

Ollin’s pipeline comprises preclinical and late-stage therapies targeting wet age-related macular degeneration (AMD), diabetic macular edema (DME), and thyroid eye disease (TED).

But its lead investigational program is for a bispecific therapy known as OLN324, originally discovered by the China-based Innovent Biologics as IBI324.

Tell me about this asset.

OLN324 is a vascular endothelial growth factor (VEGF) / Ang2 bispecific antibody with a higher potency and molar dose as well as a smaller protein format.

  • Notably: This higher potency translates to a potential for extended treatment durability (more on that here).

Its investigational indications: wet AMD and DME.

And the clinical data so far?

Looks pretty favorable for the asset, as evidenced by the phase 1b JADE study.

Among the findings: When going head-to-head against FDA-approved VABYSMO (faricimab-svoa), OLN324 demonstrated:

  • Faster + more durable drying in DME
  • Faster + greater improvements in retinal anatomy for DME and wet AMD
  • Numerically greater vision gains

Favorable indeed. Now let’s get to this acquisition.

Per the companies (and as we mentioned), J&J will purchase Ollin in a deal with a potential price tag of up to an estimated $3.3 billion.

Taking a closer look, this total amount includes:

  • $2.2 billion upfront
  • $1.125 billion (up to and approximately) comprising regulatory and commercial milestone payments

And what does that funding portion of the deal include?

As previously stated, that segment of the deal is part of a development funding agreement with Blackstone, a life sciences-focused private investment platform.

  • Specifically: Blackstone will fully finance OLN324’s phase 3 clinical program over a multi-year period for a total of $750 million.

And as a result of its investment, the firm will also be entitled to certain regulatory and sales milestone payments—plus single-digit royalties.

Also worth noting: This new funding follows on the heels of Ollin securing an oversubscribed $330 million in Series B financing this past summer for both OLN324 and OLN102 (its TED asset).

Noted. So what’s the latest on this phase 3 program?

Ollin received the all-clear from the FDA after its end-of-phase 2 meeting to initiate the global clinical program, which will evaluate OLN324 for both wet AMD and DME.

The company previously shared plans to kick off the program in H2 2026.

And is that still the plan?

As far as we can tell, yes. Neither J&J or Ollin offered a status update—and the latter’s pipeline tracker still notes H2 2026 as the target timeframe for phase 3 initiation.

Next: Why acquire Ollin?

Earlier this year, lackluster data readouts preceded J&J’s decision to discontinue clinical development of two clinical-stage retina gene therapies:

So with OLN324 under its wing, the company is looking to strengthen its position in the ophthalmic space.

Its clinical performance thus far was likely a factor in this, right?

Indeed. Kip Connor, vice president, Ophthalmology Disease Area Stronghold Leader, noted that the asset “has the potential to achieve stronger and more sustained disease control” for wet AMD and DME.

“The data generated to date are compelling and point to a potentially transformative clinical profile that could deliver more effective reduction of retinal fluid and allow more time between treatments, ultimately redefining what is possible for patients,” Connor stated.

Got it. Lastly: When is the acquisition expected to close?

By the end of 2026 (subject to a few key customary closing conditions and approvals, of course).

And keep in mind: That funding deal with Blackstone is contingent on J&J’s acquisition of Ollin.


Editor’s note: This article was updated on Nov. 16, 2026